Statins for children with familial hypercholesterolemia

Cochrane Database of Systematic Reviews

Volumn 2019, Issue 11, 2019, Pages

  Vuorio, Alpo ^a   Kuoppala, Jaana ^a   Kovanen, Petri T ^b   Humphries, Steve E ^c   Tonstad, Serena ^d   Wiegman, Albert ^e   Drogari, Euridiki ^f   Ramaswami, Uma ^g  

^a UNIVERSITY OF HELSINKI   (Finland)

^b WIHURI RESEARCH INSTITUTE   (Finland)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^d ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

^f UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^g ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; CREATINE KINASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ARTERIAL WALL THICKNESS; BRACHIAL ARTERY; CHILD HEALTH; CHOLESTEROL BLOOD LEVEL; DRUG EFFECT; DRUG SAFETY; FAMILIAL HYPERCHOLESTEROLEMIA; FLOW-MEDIATED DILATION TEST; HUMAN; META ANALYSIS; PRIORITY JOURNAL; PUBERTY; REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT PLANNING; TRIACYLGLYCEROL BLOOD LEVEL; ADOLESCENT; ADULT; BLOOD; CHILD; FEMALE; GENETICS; MALE; RANDOMIZED CONTROLLED TRIAL (TOPIC); YOUNG ADULT;

ADOLESCENT; ADULT; CHILD; CHOLESTEROL, LDL; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; YOUNG ADULT;

EID: 85074624459     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD006401.pub5     Document Type: Review

References (118)

1. Avis HJ, Hutten BA, Gagné C, Langslet G, McCrindle BW, Wiegman A, et al. Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia. Pediatric Cardiology 2010;55(11):1121-6. x-wiley/crsRef/3258728
2. Braaskamp MJ, Stefanutti C, Langslet G, Drogari E, Wiegmann A, Hounslow N, et al. Efficacy and safety of pitavastatin in children and adolescents at high future cardiovascular risk. Journal of Pediatrics 2015;167(2):338-43. x-wiley/crsRef/6211085
3. Clauss SB, Holmes KW, Hopkins P, Stein E, Cho M, Tate A, et al. Pediatrics Efficacy and safety of lovastatin therapy in adolescent girls with heterozygous familial hypercholesterolemia. Pediatrics 2005;116(3):682-8. x-wiley/crsRef/3258730
4. Couture P, Brun LD, Szots F, Lelièvre M, Gaudet D, Després J-P, et al. Association of specific LDL receptor gene mutations with differential plasma lipoprotein response to simvastatin in young French Canadian with heterozygous familial hypercholesterolemia. Arteriosclerosis Thrombosis and Vascular Biology 1998;18(6):1007-12. x-wiley/crsRef/3258732
5. De Jongh S, Stalenhoef AF, Tuohy MB, Mercuri M, Bakker HD, Kastelein JJ. Efficacy, safety and tolerability of simvastatin in children with familial hypercholesterolaemia: rationale, design, and baseline characteristics. Clinical Biochemistry and Metabolism 2003;11(32):157-62. x-wiley/crsRef/3258734
6. de Jongh S, Lilien MR, op't Roodt J, Stroes ES, Bakker HD, Kastelein JJ. Early statin therapy restores endothelial function in children with familial hypercholesterolemia. Journal of the American College of Cardiology 2002;40(12):2117-21. x-wiley/crsRef/3258735
7. de Jongh S, Ose L, Szamosi T, Gagné C, Lambert M, Scott R, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: A randomized, double-blind, placebo-controlled trial with simvastatin. Circulation 2002;106(17):2231-7. x-wiley/crsRef/3258736
8. de Jongh S, Stalenhoef AF, Tuohy MB, Mercuri M, Bakker HD, Kastelein JJ. Efficacy, safety and tolerability of simvastatin in children with familial hypercholesterolaemia. Clinical Drug Investigation 2002;22(8):533-40. x-wiley/crsRef/3258737
9. Knipscheer HC, Boelen CC, Kastelein JJ, van Diermen DE, Groenemeijer BE, van den Ende A, et al. Short-term efficacy and safety of pravastatin in 72 children with familial hypercholesterolemia. Pediatric Research 1996;39(5):867-71. x-wiley/crsRef/3258739
10. McCrindle BW, Ose L, Marais AD. Efficacy and safety of atorvastatin in children and adolescents with a familial hypercholesterolemia or severe hyperlipidemia: A multicenter, randomized, placebo-controlled trial. Journal of Pediatrics 2003;143(1):74-80. x-wiley/crsRef/3258741
11. Stein EA, Illingworth DR, Kwiterovich Jr. PO, Liacouras CA, Siimes MA, Jacobson MS, et al. Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia. JAMA 1999;281(2):137-44. x-wiley/crsRef/3258743
12. Wiegman A, Hutten BA, de Groot E, Rodenburg J, Bakker HD, Büller HR, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia. JAMA 2004;292(3):331-7. x-wiley/crsRef/3258745
13. Athyros VG, Papageorgiou AA, KOntopoulos AG. Long-term treatment with atorvastatin in adolescent males with heterozygous familial hypercholesterolemia. Atherosclerosis 2002;163(1):205-6. x-wiley/crsRef/3258747
14. Braamskamp MJ, Kusters DM, Wiegmann A, Avis HJ, Wijburg FA, Kastelein JJ, et al. Gonadal steroids, gonadotropins and DHEAS in young adults with familial hypercholesterolemia who had initiated statin therapy in childhood. Atherosclerosis 2015;241(2):427-32. x-wiley/crsRef/6211087
15. Braaskamp MJ, Langslet G, McCrindle BW, Cassiman D, Francis GA, Gagné C, et al. Efficacy and safety of rosuvastatin therapy in children and adolescents with familial hypercholesterolemia: Results from the CHARON study. Journal of Clinical Lipidology 2015;9(6):741-50. x-wiley/crsRef/6211089
16. Carreau V, Girardet JP, Bruckert E. Long-term follow-up of statin treatment in a cohort of children with familial hypercholesterolemia: Efficacy and tolerability. Pediatric Drugs 2011;13(4):267-75. x-wiley/crsRef/3258749
17. Chan DC, Pang J, Barrett PH, Sullivan DR, Mori TA, Burnett JR, et al. Effect of omega-3 fatty acid supplementation on arterial elasticity in patients with familial hypercholesterolaemia on statin therapy. Nutrition, Metabolism and Cardiovascular Diseases 2016;26(12):1140-5. [CENTRAL: 1247168; CRS: 5500050000000549; EMBASE: 613255561]x-wiley/crsRef/6211091
18. Dirisamer A, Hachemian N, Bucek RA, Wolf F, Reiter M, Widhalm K. The effect of low-dose simvastatin in children with familial hypercholesterolemia: a 1-year observation. European Journal of Pediatrics 2003;162(6):421-5. x-wiley/crsRef/3258751
19. Gandelman K, Glue P, Laskey R, Jones J, LaBadie R, Ose L. An eight-week trial investigating the efficacy and tolerability of atorvastatin for children and adolescents with heterozygous familial hypercholesterolemia. Pediatric Cardiology 2011;32(4):433-41. x-wiley/crsRef/3258753
20. Harada-Shiba M, Kastelein JJ, Hovingh K, Ray KK, Ohtake A, Arisaka O, et al. Efficacy and safety of pitvastatin in children and adolescents with familial hypercholesterolemia in Japan and Europe. Journal of Atherosclerosis and Thrombosis 2018;25:422-429. x-wiley/crsRef/12237136
21. Hedman M, Neuvonen PJ, Neuvonen N, Antikainen M. Pharmacokinetics and pharmacodynamics of pravastatin in children with familial hypercholesterolemia. Clinical Pharmacology and Therapy 2003;74(2):178-85. x-wiley/crsRef/3258755
22. Hedman M, Matikainen T, Fohr A, Lappi M, Piippo S, Nuutinen M, et al. Efficacy and safety of pravastatin in children and adolescents with heterozygous familial hypercholesterolemia: A prospective clinical follow-up study. Journal of Clinical Endocrinology and Metabolism 2005;90(4):1942-52. x-wiley/crsRef/3258757
23. Lambert M, Lupien PJ, Gagne C, Levy E, Blaichman S, Langlois S, et al. Treatment of familial hypercholesterolemia in children and adolescents: Effect of lovastatin. Pediatrics 1996;97(5):619-28. x-wiley/crsRef/3258759
24. Langslet G, Breazna A, Drogari E. A 3-year study of atorvastatin in children and adolescents with heterozygous familial hypercholesterolemia. Journal of Clinical Lipidology 2016;10(5):1153-62. x-wiley/crsRef/6211093
25. McCrindle BW, Helsden E, Cullen-Dean G, Conner WT. A randomized crossover trial of combination pharmacologic therapy in children with familial hyperlipidemia. Pediatric Research 2002;51(6):715-21. x-wiley/crsRef/3258761
26. Raal FJ, Pitcher G, Rubinsztein DC, Lingenhel A, Utermann G. Statin therapy in a kindred with both apolipoprotein B and low-density lipoprotein receptor gene defects. Atherosclerosis 1997;129(1):97-102. x-wiley/crsRef/3258763
27. Sinzinger H, O'Grady J. Professional athletes suffering from familial hypercholesterolemia rarely tolerate statin treatment because of muscular problems. British Journal of Clinical Pharmacology 2004;57(4):525-8. x-wiley/crsRef/3258765
28. Stefanutti C, Lucani G, Vivenzio A, Di Giacomo S. Diet only and diet plus simvastatin in the treatment of heterozygous familial hypercholesterolemia in childhood. Drugs Under Experimental and Clinical Research 1999;25(1):23-8. x-wiley/crsRef/3258767
29. Stein EA. Treatment of familial hypercholesterolemia with drugs in children. Arteriosclerosis 1989;9(Suppl 1):l145-51. x-wiley/crsRef/3258769
30. Stein EA, Dann EJ, Wiegmann A, Skovby F, Gaudet D, Sokal E, et al. A randomized, double-blind, placebo-controlled, multi-center, Cross-over study of rosuvastatin in children and adolescents (aged 6 to <18 years) with homozygous familial hypercholesterolemia (HOFH). JACC 2016;67(13):1855. x-wiley/crsRef/6211095
31. Tada H, Kobayashi J, Kawashiri MA, Miashita K, Nohara A, Inazu A, et al. Changes in lipoprotein lipase and endothelial lipase mass in familial hypercholesterolemia during three-drug lipid-lowering combination therapy. Lipids in Health and Disease 2016;15:66. x-wiley/crsRef/6211097
32. Teramoto T, Kobayashi M, Tasaki H, Yagyu H, Higashikata T, Takagi Y, et al. Efficacy and safety of alirocumab in Japanese patients With heterozygous familial hypercholesterolemia or at high cardiovascular risk with hypercholesterolemia not adequately controlled with statins - ODYSSEY JAPAN Randomized Controlled Trial. Ciruculation Journal 2016;80(9):1980-7. x-wiley/crsRef/6211099
33. van der Graaf A, Nieman MC, Firth JC, Wolmarans KH, Marais AD, De GE. Efficacy and safety of fluvastatin in children and adolescents with heterozygous familial hypercholesterolemia. Acta Paediatrica 2006;95(11):1461-6. x-wiley/crsRef/3258771
34. Arambepola C, Farmer AJ, Perera R, Neil HA. Statin treatment for children and adolescents with heterozygous familial hypercholesterolaemia: A systematic review and meta-analysis. Atherosclerosis 2007;195(2):339-47.
35. Avis HJ, Vissres EA, Stein FA, Wijburg MD, Trip JJP, Kastelein JJ, et al. A systematic review and meta-analysis of statin therapy in children with familial hypercholesterolemia. Arteriosclerosis Thrombosis and Vascular Biology 2007;27(8):1803-10.
36. Backes JM, Howard PA. Association of HMG-CoA reductase inhibitors with neuropathy. Annals of Pharmacotherapy 2003;37(2):274-8.
37. Bays H. Statin safety: An overview an assessment of the data - 2005. American Journal of Cardiology 2006;97(8A):6C-26C.
38. Benn M, Watts GF, Tybjærg-Hansen A, Nordetsgaard BG. Mutations causative of familial hypercholesterolaemia: screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217. European Heart Journal 2016;37(17):1384-94.
39. Besseling J, Kastelein JJ, Defesche JC, Hutten BA, Hovingh GK. Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus. JAMA 2015;313(10):358-61.
40. Bradford RH, Shear CL, Chremos AN, Dujovne C, Dowton M, Franklin FA, et al. Expanded clinical evaluation of lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Archives of Internal Medicine 1991;151(1):43-9.
41. Brass LM, Alberts MJ, Sparks L. National Lipid Association Statin Safety Task Force Neurology Expert Panel: An assessment of statin safety by neurologist. American Journal of Cardiology 2006;97(8A):86C-88C.
42. Cenedella RJ. Cholesterol and cataracts. Survey of Opthalmology 1996;40(4):320-37.
43. Chalasani N, Aljadhey H, Kesterson J, Murray MD, Hall SD. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 2004;126(5):1287-92.
44. Chodick G, Heymann AD, Flash S, Kokia E, Shalev V. Persistence with statins and incident cataract: a population-based historical cohort study. Annals of Epidemiology 2010;20(2):136-42.
45. Chong PH, Boskovich A, Sevkovic N, Bartt RE. Statin-associated peripheral neuropathy: Review of the literature. Pharmacotherapy 2004;24(9):1194-203.
46. Cohen DE, Anania FA, Chalasani N. An assessment of statin safety by hepatologists. American Journal of Cardiology 2007;8(Suppl 1):S77-S81.
47. Daniels SR, Greer FR, Committee on Nutrition. Lipid screening and cardiovascular health in children. Pediatrics 2008;122(1):198-208.
48. de Denus S, Spinler SA, Miller K, Peterson AM. Statins and live toxicity: a meta-analysis. Pharmacotherapy 2004;24(5):584-91.
49. de Jongh S, Lilien MR, op't Roodt J, Stroes ES, Bakker HD, Kastelein JJ. Early statin therapy restores endothelial function in children with familial hypercholesterolemia. Journal of the American College of Cardiology 2002;40(12):2117-21.
50. Descamps OS, Tenoutasse S, Stephenne X, Gies I, Beauloye V, Lebrethon MC, et al. Management of familial hypercholesterolemia in children and young adults: consensus paper developed by a panel of lipidologists, cardiologists, paediatricians, nutritionists, gastroenterologists, general practitioners and a patient organization. Atherosclerosis 2012;218(2):272-80.
51. Fong DS, Poon KY. Recent statin use and cataract surgery. American Journal of Opthalmology 2012;153(2):222-8.
52. Futema M, Whittall RA, Kiley A, Steel LK, Cooper JA, Badmus E, et al. Analysis of the frequency and spectrum on mutation recognised to cause familial hypercholesterolaemia in routine clinical practise in a UK specialist hospital clinic. Atherosclerosis 2013;229(1):161-8.
53. Futema M, Shah S, Cooper JA, Li K, Whittall RA, Sharifi M, et al. Refinement of variant selection for the LDL cholesterol genetic risk score in the diagnosis of the polygenic form of clinical familial hypercholesterolemia and replication in samples from 6 countries. Clinical Chemistry 2015;61(1):231-8.
54. Goldberg AC, Hopkins PN, Toth PP, Ballantyne CM, Rader DJ, Robinson JG, et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. Journal of Clinical Lipidology 2011;5(3 Suppl):S1-S8.
55. Goldstein JL, Helgeson JA, Brown MS. Inhibition of cholesterol synthesis with compactin renders growth of cultured cells dependent on the low density lipoprotein receptor. Journal of Biological Chemistry 1979;254(12):5403-9.
56. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990;343(6257):425-30.
57. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D editor(s). The Metabolic Bases of Inherited Diseases. 7th Edition. New York, NY: McGraw-Hill Book Co, 1995:1981-2030.
58. Golomb BA. The importance of monitoring adverse events in statin, and other, clinical trials. Clinica Investigation 2013;3(10):913-6.
59. Graham CA, McIlhatton BP, Kirk CW, Beattie ED, Lyttle K, Hart P, et al. Genetic screening protocol for familial hypercholesterolemia which includes splicing defects gives an improved mutation detection rate. Atherosclerosis 2005;182(2):331-40.
60. Harris ML, Bron AJ, Brown NAkeech AC, Wallendszus KR, Armitage JM, MacMahon S, et al. Absence of effect of simvastatin on the progression of lens opacitis in a randomised placebo controlled study. Oxford Cholesterol Study Group. Bristish Journal of Opthalmology 1995;79(11):996-1002.
61. Heath KE, Gudnason V, Humphries SE, Seed M. The type of mutation in the low density lipoprotein receptor gene influences the cholesterol-lowering response of the HMG-CoA reductase inhibitor simvastatin in patients with heterozygous familial hypercholesterolemia. Atherosclerosis 1999;143(1):41-54.
62. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
63. Higgins JP, Deeks JJ, editor(s). Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
64. Higgins JP, Altman DG, editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
65. Hippisley-Cox, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ 2010;340:c2197.
66. Hoffmann U, Dirisamer A, Heher S, Kostner K, Widhalm K, Neunteufl T. Relation of flow-mediated vasodilatation and coronary arterial calcium in young patients with heterozygous familial hypercholesterolemia. American Journal of Cardiology 2002;90(1):70-3.
67. Humphries SE, Cranston T, Allen M, Middleton-Price H, Fernandez MC, Senior V, et al. Mutational analysis in UK patients with a clinical diagnosis of familial hypercholesterolemia: relationship with plasma lipid traits, heart disease risk and utility in relative tracing. Journal of Molecular Medicine (Berl) 2006;84(3):203-14.
68. Humphries SE, Whittall RA, Hubbart CS, Maplebeck S, Cooper JA, Soutar A, et al. Genetic causes of Familial Hypercholesterolaemia in UK patients: Relation to plasma lipid levels and coronary heart disease risk. Journal of Medical Genetics 2006;43(12):943-9.
69. Iacocca MA, Chora JR, Carrié A, Freiberger T, Leigh SE, Defesche JC, et al. ClinVar database of global familial hypercholesterolemia-associated DNA variants. Human Mutation 2018;39(11):2018.
70. Joy TR, Hegele RA. Narrative Review: statin-related myopathy. Annals of Internal Medicine 2009;150(12):858-68.
71. Joyce NR, Zachariah JP, Eaton CB, Trivedi AN, Wellenius GA. Statin use and the risk of type 2 diabetes mellitus in children adolescents. Acta Pediatrica 2017;17(5):515-22.
72. Jüni P, Altman DG, Egger M. Assessing the quality of controlled clinical trials. BMJ 2001;323(7303):42-6.
73. Khera A, Won HH, Peloso GM, Lawson KS, Bartz TM, Deng X, et al. Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia. Journal American College of Cardiology 2016;67(22):2578-89.
74. Koeijvoets KC, Rodenburg J, Hutten BA, Wiegman A, Kastelein JJ, Sijbrands EJ. Low-density lipoprotein receptor genotype and response to pravastatin in children with familial hypercholesterolemia: substudy of an intima-media thickness trial. Circulation 2005;112(20):3168-73.
75. Kotze MJ, De Villiers WJ, Steyn K, Kriek JA, Marais AD, Langenhoven E, et al. Phenotypic variation among familial hypercholesterolemics heterozygous for either one of two Afrikaner founder LDL receptor mutations. Arteriosclerosis and Thrombosis 1993;13(10):1460-8.
76. Kusters DM, Avis HJ, de Groot E, Wijburg FA, Kastelein JJ, Wiegmann A, et al. Ten-year follow-up after initiation of statin therapy in children with familial hyeprcholesterolemia. JAMA 2014;312(10):1055-7.
77. Kwiterovich PO Jr, Fredrikson DS, Levy RI. Familial hypercholesterolemia (one form of familial type II hyperlipoproteinemia). A study of its biochemical, genetic and clinical presentation in childhood. Journal of Clinical Investigation 1974;53(5):1237-49.
78. Law M, Rudnicka AR. Statin safety: A systematic review. American Journal of Cardiology 2006;97(8A):52C-60C.
79. Leigh S, Futema M, Taylor-Beadling A, Williams M, den Dunnen JT, Humphries SE. The UCL low-density lipoprotein receptor gene variant database: pathogenicity update. Journal of Medical Genetics 2016;54(4):217-23.
80. Leonard JV, Fosbrooke AS, Lloyd JK, Wolff OH. Screening for familial hyper-beta-lipoproteinemia in children in hospital. Archives of Diseases in Children 1976;51(11):842-7.
81. Leuschen J, Mortensen EM, Frei CR, Mansi EA, Panday V, Mansi I. Association of statin use with cataracts: a propensity score-matched analysis. JAMA Opthalmolology 2013;131(11):1427-34.
82. Mabuchi H, Koizumi J, Shimizu M, Takeda R. Development of coronary heart disease in familial hypercholesterolemia. Circulation 1989;79(2):225-32.
83. McCrindle BW, Urbina EM, Dennison BA, Jacobson MS, Steinberger J, Rocchini AP, et al. Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. Circulation 2007;115(14):1948-67.
84. McCrindle BW. Familial hypercholesterolemia in children and adolescents. Current Opinion in Lipidology 2012;23(6):525-31.
85. McKenney JM, Davidson MH, Jacobson TA, Guyton JR. Final conclusions and recommendations of the National Lipid Association Statin Safety Task Force. American Journal of Cardiology 2006;97(8A):89C-94C.
86. Miltiadous G, Xenophontos S, Bairaktari E, Ganotakis M, Cariolou M, Elisaf M. Genetic and environmental factors affecting the response to statin therapy in patients with molecularly defined familial hypercholesterolaemia. Pharmagogenetic Genomics 2005;15(4):219-25.
87. Myant NB. Familial defective apolipoprotein B-100: A review, including some comparisons with familial hypercholesterolaemia. Atherosclerosis 1993;104(1-2):1-18.
88. Navarese EP, Buffon A, Andreotti F, Kozinski M, Welton N, Fabiszak T, et al. Meta-anaysis of impact of different types and doses of statins on new-onset diabetes mellitus. American Journal of Cardiology 2013;111(8):1123-30.
89. National Institute of Clinical Excellence. Identification and management of familial hypercholesterolaemia - clinical guideline CG71. http://www.nice.org.uk/nicemedia/pdf/CG071NICEGuideline.pdf (accessed 01 October 2013).
90. Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana I, Descamps OS, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. European Heart Journal 2013;34(45):3478-90.
91. O'Connor P, Feely J, Shepherd J. Lipid lowering drugs. BMJ 1990;300(6725):667-72.
92. Pang J, Landsberg PJ, Watts GF. International developments in the care of familial hypercholesterolemia: Where now and where to next?. Journal of Atherosclerosis and Thrombosis 2016;23(5):505-19.
93. Pasternak RC, Smith SC, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C, et al. ACC/AHA/NHLBI Clinical advisory on the use and safety of statins. Circulation 2002;106(8):1024-8.
94. Pedersen TR, Berg K, Cook TJ, Faergeman O, Haghfelt T, Kjekshus J, et al. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Archives of Internal Medicine 1996;156(18):2085-92.
95. Poustie VJ, Rutherford P. Dietary treatment for familial hypercholesterolaemia. Cochrane Database of Systematic Reviews 2001, Issue 2. [DOI: 10.1002/14651858.CD001918]
96. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010;375(9716):735-42.
97. Scottish Intercollegiate Guidelines Network. Risk estimation and the prevention of cardiovascular disease. www.sign.ac.uk/pdf/sign97.pdf (accessed 01 October 2013).
98. Sjouke B, Kusters DM, Besseling J, Defesche JC, Sijbrands EJ, Roeters van Lennep JE, et al. Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome. European Heart Journal 2015;36(9):560-5.
99. Skoumas J, Liontou C, Chrysohoou C, Masoura C, Aznaouridis K, Pitsavos C, et al. Statin therapy and risk of diabetes in patients with heterozygous familial hypercholesterolemia or familial combined hyperlipidemia. Atherosclerosis 2014;237(1):140-5.
100. Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. New England Journal of Medicine 2002;346(7):539-40.
101. Starr B, Hadfiled SG, Hutten BA, Landsberg P, Leren TP, Damgaard D, et al. Development of sensitive and specific age- and gender-specific low-density lipoprotein cholesterol cutoffs for diagnosis of first-degree relatives with familial hypercholesterolaemia in cascade testing. Clinical Chemistry and Laboratory Medicine 2008;46(6):791-803.
102. Sullivan DR, Hamilton-Craig I, van Bockxmeer F, Watts GF, CSANZ Cardiac Genetics Diseases Council Writing Group. INTERIM guidelines for the diagnosis and management of familial hypercholesterolaemia. Heart Lung and Circulation 2012;21(3):159-62.
103. Sun XM, Patel D, Knight BL, Soutar AK. Influence of genotype at the low density lipoprotein (LDL) receptor gene locus on the clinical phenotype and response to lipid-lowering drug therapy in heterozygous familial hypercholesterolemia. The Familial Hypercholesterolaemia Regression Study Group. Atherosclerosis 1998;136(1):175-85.
104. Swerdlow DI, Presii D, Kuchenbaecker KB, Holmes MV, Engmann JE, Shah T, et al. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet 2015;385(9965):351-61.
105. Talmud PJ, Shah S, Whittall R, Futema M, Howard P, Cooper JA, et al. Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study. Lancet 2013;381(9874):1293-1301.
106. Tonstad S, Joakimsen O, Stensland-Bugge E, Leren TP, Ose L, Russell D, et al. Risk factors related to carotid intima-media thickness and plaque in children with familial hypercholesterolemia and control subjects. Arteriosclerosis, Thrombosis, and Vascular Biology 1996;16(8):984-91.
107. Umans-Eckenhausen MA, Sijbrands EJ, Kastelein JJ, Defesche JC. Low-density lipoprotein receptor gene mutations and cardiovascular risk in a large genetic cascade screening population. Circulation 2002;106(24):3031-6.
108. van der Graaf A, Avis HJ, Kusters DM, Vissers MN, Hutten BA, Defesche JC, et al. Molecular basis of autosomal dominant hypercholesterolemia. Circulation 2011;123(11):1167-73.
109. Vlahos AP, Naka KK, Bechlioulis A, Theoharis P, Vakalis K, Moutzouri E, et al. Endothelial dysfunction, but not structural atherosclerosis, is evident early in children with heterozygous familial hypercholesterolemia. Pediatric Cardiology 2014;35(1):63-70.
110. Vohl MC, Szots F, Leliévre M, Lupien PJ, Bergeron J, Gagné C, et al. Influence of LDL receptor gene mutation and apo E polymorphis on liporpotein response to simvastatin treatment among adolescents with heterozygous familial hypercholesterolemia. Atherosclerosis 2002;160(2):361-8.
111. Vuorio AF, Aalto-Setälä K, Koivisto UM, Turtola H, Nissen H, Kovanen PT, et al. Familial hypercholesterolaemia in Finland: Common, rare and mild mutations of the LDL receptor and their clinical consequences. Annals of Medicine 2001;33(6):410-21.
112. Vuorio A, Docherty KF, Humphries SE, Kuoppala J, Kovanen PT. Statin treatment of children with familial hypercholesterolemia - trying to balance incomplete evidence of long-term safety and clinical accountability: Are we approaching a consensus?. Atherosclerosis 2013;226(2):315-20.
113. Vuorio A, Strandberg T, Schneider WJ, Kovanen PT. Statins and new-onset diabetes mellitus - a risk lacking in familial hypercholesterolaemia. Journal of Internal Medicine 2016;279(4):358-61.
114. Wald DS, Bestwick JP, Morris JK, Whyte K, Jenkins L, Wald NJ. Child-parent familial hypercholesterolemia screening in primary care. New England Journal of Medicine 2016;375(17):1628-37.
115. Wray R, Neil H, Rees J. Screening for hyperlipidaemia in childhood. Recommendations of the British Hyperlipidaemia Association. Journal of Royal College of Physicians London 1996;30(2):115-8.
116. Vuorio A, Kuoppala J, Kovanen PT, Humphries SE, Strandberg T, Tonstad S, et al. Statins for children with familial hypercholesterolemia. Cochrane Database of Systematic Reviews 2010, Issue 7. [DOI: 10.1002/14651858.CD006401.pub2]
117. Vuorio A, Kuoppala J, Kovanen PT, Humphries SE, Tonstad S, Wiegman A, Drogari E. Statins for children with familial hypercholesterolemia. Cochrane Database of Systematic Reviews 2014, Issue 7. [DOI: 10.1002/14651858.CD006401.pub3]
118. Vuorio A, Kuoppala J, Kovanen PT, Humphries SE, Tonstad S, Wiegman A, et al. Statins for children with familial hypercholesterolemia. Cochrane Database of Systematic Reviews 2017, Issue 7. [DOI: 10.1002/14651858.CD006401.pub3]